B-cell receptors (BCRs) are transmembrane proteins on the surface of B cells and consist of immunoglobulin molecules that form type I transmembrane receptor proteins. BCRs control the activation of B cells through biochemical signaling and physical acquisition of antigens from immune synapses. B cells are able to recognize, bind and endocytose antigens through the BCR and ultimately make antigen delivery. BCR has antigen binding specificity, which depends on the diversity of BCR genes. BCR genes can constitute a huge BCR library, giving individuals a great potential to recognize various antigens and produce specific antibodies.
T cell receptors (TCRs) are on the surface of T cells responsible for the specific recognition of antigens presented by the major histocompatibility complex (MHC). Unlike BCRs, TCRs cannot recognize free antigens. In general, TCRs possess low affinity and no specificity for antigens, and their role is to trigger a series of biochemical reactions by specific binding to MHC-presented peptides, which ultimately activate T cells through numerous co-receptors, enzymes and transcription factors. TCR genes are the most complex and highly variable genes in the human genome.
B cells and T cells are important immune cells involved in the immune process, while BCR and TCR are important membrane proteins that determine the function of immune cells. Changes in BCR and TCR are importantly linked to the development of diseases. BCR and TCR sequencing enables analysis of disease mechanisms and monitoring of disease development from an immunological perspective, such as cancer, autoimmune diseases, inflammation, infectious diseases, etc.
BCR and TCR sequencing provided by CD Genomics is mainly applied in the field of immuno-oncology research, including tumor immune response, diagnosis and prevention mechanism. The sum of TCR of all T cells and BCR of B cells are respectively called TCR profiling and BCR profiling. As tumor arises and progresses, both TCR profiling and BCR profiling will change significantly. Stepwise V(D)J recombination during B or T-cell development mainly contributes to the great diversity, clonality and dynamics of BCR or TCR repertoires in the adaptive immune system. Based on our mainstream sequencing technologies, instruments, and team of experts, CD Genomics is well positioned to provide you with high-throughput BCR and TCR sequencing aimed at overcoming diversity. Our strategy enables high resolution and panoramic analysis of BCR and TCR with the workflow shown below.
01. Sample requirements
| Sample Type | DNA Amount | DNA Concentration | Purity |
|---|---|---|---|
| Total DNA from cells, blood, saliva, tissue, formalin-fixed samples, fresh frozen tissue samples, paraffin-embedded tissues, cancer liquid biopsies, etc. | ≥ 200 ng | ≥ 20 ng/μL | OD260/280=1.8 - 2.0; no degradation, no contamination |
02. Library construction and NGS
Low-cost and high-accuracy Illumina / MGI NGS platform
03. Bioinformatics Analysis
BCR/TCR gene rearrangements and changes in abundance are analyzed to investigate the mechanisms of tumor immune response, causes of immune tolerance, and forms of immune regulation. BCR and TCR sequencing from CD Genomics can specifically serve the following immuno-oncology analysis components.
CD Genomics is committed to combining professional project protocol guidance and standardized analysis processes to ensure that your project is performed accurately and quickly. If you are interested in CD Genomics' BCR and TCR sequencing workflow in the field of immuno-oncology, please feel free to contact us now.
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
